Award recordCONTRACT

ADVANCED ACCELERATOR APPLICATIONS USA INC

PIID 36C26125F0002· VHA· 261-NETWORK CONTRACT OFFICE 21 (36C261)· 6505 · DRUGS AND BIOLOGICALS· FY2025· $1,693,772 net obligations· UEI JNM4NBNHFE66· NY

Description

DE-OB FY25 AND CLOSE OUT. PLUVICTO PROSTATE CANCER THERAPY VANCHCS - CLIN 0002 QUANTITY DECREASE.

Base award description: PLUVICTO PROSTATE CANCER THERAPY VANCHCS

First action · last action
2024-10-01 · 2026-04-09
Transactions
4
First transaction's obligation
$4,370,400
Base + all options value (sum of deltas)
$1,693,772
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
36F79719D0169
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 4 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$4,370,400$0Base award · 2024-10-01 · this action $4,370,400 · running total $4,370,400Modification P00001 · 2025-04-11 · this action -$1,182,083 · running total $3,188,317Modification P00002 · 2025-06-11 · this action -$1,030,103 · running total $2,158,213Modification P00003 · 2026-04-09 · this action -$464,441 · running total $1,693,772
  • Base2024-10-01+$4,370,400= $4,370,400
  • Mod P000012025-04-11-$1,182,083= $3,188,317
  • Mod P000022025-06-11-$1,030,103= $2,158,213
  • Mod P000032026-04-09-$464,441= $1,693,772
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2024-10-01+$4,370,400$4,370,400PLUVICTO PROSTATE CANCER THERAPY VANCHCS
Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE2025-04-11−$1,182,083$3,188,317PLUVICTO PROSTATE CANCER THERAPY VANCHCS - DEOBLIGATION
Mod P00002· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE2025-06-11−$1,030,103$2,158,213PLUVICTO PROSTATE CANCER THERAPY VANCHCS - CLIN 0002 QUANTITY DECREASE AND DEOBLIGATION.
Mod P00003· CLOSE OUT2026-04-09−$464,441$1,693,772DE-OB FY25 AND CLOSE OUT. PLUVICTO PROSTATE CANCER THERAPY VANCHCS - CLIN 0002 QUANTITY DECREASE.

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI JNM4NBNHFE66)

AwardOffice · PSC / listingNet obligationsFY
36C25526N0132255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS$1,200,000FY2026
36C26026N0121260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$996,874FY2026
36C24926N0263249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS$823,062FY2026
36C25525N0282255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS$166,146FY2025
36C25525N0176255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS$1,362,395FY2025
36C25225F0044252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS$631,354FY2025

Other recipients under 6505 from 261-NETWORK CONTRACT OFFICE 21 (36C261) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C26126P1178OPTUM FRONTIER THERAPIES II, LLC261-NETWORK CONTRACT OFFICE 21 (36C261)$58,374FY2026
36C26126P1102ENVIGO RMS LLC261-NETWORK CONTRACT OFFICE 21 (36C261)$74,586FY2026
36C26126P096110X GENOMICS, INC.261-NETWORK CONTRACT OFFICE 21 (36C261)$34,600FY2026
36C26126P0997SIERRA RADIOPHARMACY LLC261-NETWORK CONTRACT OFFICE 21 (36C261)$247,204FY2026
36C26126P1008OPTUM FRONTIER THERAPIES II, LLC261-NETWORK CONTRACT OFFICE 21 (36C261)$58,374FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26125F0002_3600_36F79719D0169_3600 · retrieved 2026-09-26.